ESMO Breast Cancer 2023 Congress Coverage
K

ESMO Breast Cancer 2023 Phase 3b LUCY Trial Subgroup Analysis: Clinical Effectiveness of Olaparib in BRCAm, HER2- mBC by ER Expression Level

By ESMO Breast Cancer 2023 Congress Coverage FEATURING Karen Gelmon
By ESMO Breast Cancer 2023 Congress Coverage FEATURING Karen Gelmon
98 views
May 25, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
09:19
Insights from 2023 SABCS

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…

Feat. K. Kalinsky
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
23:13
Keck School of Medicine of USC

NRG-BR009 ("OFSET") Study: Evaluating the Addition of Adju…

Feat. T. Mamounas
29:40
Insights from 2023 SABCS

Year in Review: Metastatic Breast Cancer

Feat. M. Mac Gregor
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
05:45
SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

07:34
PrecisCa

Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…

Feat. M. Pegram
13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar